Mr. Michael Frank reports
REVIVE THERAPEUTICS ANNOUNCES U.S. FDA APPROVAL OF CONFIRMATORY PHASE 3 CLINICAL TRIAL FOR BUCILLAMINE IN COVID-19
The U.S. Food and Drug Administration (FDA) has approved Revive Therapeutics Ltd. to proceed with a randomized, double-blind, placebo-controlled confirmatory phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.
"The FDA approval of the phase 3 study to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19 is a tremendous milestone for Revive, and I am very proud of the dedication of our team and partners to bring forward a potential new treatment option for patients with a confirmed diagnosis of COVID-19 globally," said Michael Frank, Revive's chief executive officer. "We thank the FDA for recognizing the importance of this phase 3 study, and we are now focused on executing on our plans for initiating the clinical trial in an expeditious manner."
About the phase 3 confirmatory clinical study
The phase 3 confirmatory clinical study, titled, "A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19," will enroll up to 1,000 patients that will be randomized 1:1:1 to receive Bucillamine 100 milligrams three times a day (TID), Bucillamine 200 mg TID or placebo TID for up to 14 days. The primary objective is to compare frequency of hospitalization or death in patients with mild-moderate COVID-19 receiving Bucillamine therapy with those receiving the placebo. The primary end point is the proportion of patients meeting a composite end point of hospitalization or death from the time of first dose through day 28 following randomization. Efficacy will be assessed by comparison of: clinical outcome (death or hospitalization); disease severity using the eight-category National Institute of Allergy and Infectious Diseases COVID-19 ordinal scale; supplemental oxygen use; and progression of COVID-19 between patients receiving standard of care plus Bucillamine (high dose and/or low dose) and patients receiving standard of care plus placebo. Safety will be assessed by reported pretreatment adverse events and treatment-emergent adverse events (including serious adverse events and adverse events of special interest), laboratory values (hematology and serum chemistry), vital signs (heart rate, respiratory rate and temperature) and peripheral oxygen saturation.
An interim analysis will be performed by an independent data and safety monitoring board (DSMB) after 210 patients have been treated and followed up for a total of 28 days after randomization. The better-performing Bucillamine dose at the interim analysis will be selected, and patients will then be randomized 2:1 to the selected Bucillamine dose or placebo. Additional interim analyses will be performed after 400, 600 and 800 patients have reached this same posttreatment time point. The independent DSMB will actively monitor interim data for the continuing safety of patients and will recommend continuation, stopping or changes to the conduct of the study based on the interim analysis reports.
Scientific rationale of Bucillamine for COVID-19
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells. N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to increase antioxidant activity of cellular glutathione. Bucillamine has a well-known safety profile and has been prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC. The drug is non-toxic, with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via increasing glutathione activity and other anti-inflammatory activity, to lessen the destructive consequences of the SARS-CoV2 infection in the lungs and attenuate the clinical course of COVID-19.
The company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 at this time.
About Revive Therapeutics Ltd.
Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.